Gloria C Chiang1, Eileen Chang2, Sneha Pandya2, Amy Kuceyeski2, James Hu2, Richard Isaacson3, Christine Ganzer4, Aaron Schulman5, Vivian Sobel5, Shankar Vallabhajosula2, Lisa Ravdin3. 1. Department of Radiology, Division of Neuroradiology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, United States. Electronic address: gcc9004@med.cornell.edu. 2. Department of Radiology, Division of Neuroradiology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, United States. 3. Department of Neurology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, United States. 4. Department of Nursing, Hunter-Bellevue School of Nursing, New York, NY, United States. 5. Department of Medicine, Division of Endocrinology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, United States.
Abstract
BACKGROUND: To determine the effects of Type 2 diabetes (DM2) on levels of brain amyloidosis and cognition in a community-dwelling cohort of nondemented elderly individuals. METHODS: 33 subjects (16 DM2, 17 nondiabetic) were prospectively recruited. Subjects underwent a PET scan using the amyloid tracer, Pittsburgh Compound B, and a neuropsychological evaluation. Associations between DM2, brain amyloidosis, and cognition were assessed using multivariate regressions, adjusting for age and APOE4 status. RESULTS: DM2 subjects had lower global cognitive function (p=0.018), as measured by the Repeatable Battery for the Assessment of Neuropsychological Status. There was no difference in brain amyloidosis between groups (p=0.25). CONCLUSIONS: Community-dwelling, nondemented individuals with DM2 had greater cognitive deficits, which do not appear to be mediated by brain amyloidosis. Further studies exploring potential mediators of these cognitive deficits should be performed.
BACKGROUND: To determine the effects of Type 2 diabetes (DM2) on levels of brain amyloidosis and cognition in a community-dwelling cohort of nondemented elderly individuals. METHODS: 33 subjects (16 DM2, 17 nondiabetic) were prospectively recruited. Subjects underwent a PET scan using the amyloid tracer, Pittsburgh Compound B, and a neuropsychological evaluation. Associations between DM2, brain amyloidosis, and cognition were assessed using multivariate regressions, adjusting for age and APOE4 status. RESULTS:DM2 subjects had lower global cognitive function (p=0.018), as measured by the Repeatable Battery for the Assessment of Neuropsychological Status. There was no difference in brain amyloidosis between groups (p=0.25). CONCLUSIONS: Community-dwelling, nondemented individuals with DM2 had greater cognitive deficits, which do not appear to be mediated by brain amyloidosis. Further studies exploring potential mediators of these cognitive deficits should be performed.
Authors: Niraj M Parikh; Robert O Morgan; Mark E Kunik; Hua Chen; Rajender R Aparasu; Ravi K Yadav; Paul E Schulz; Michael L Johnson Journal: Int J Geriatr Psychiatry Date: 2010-10-04 Impact factor: 3.485
Authors: E van Exel; J Gussekloo; A J de Craen; A Bootsma-van der Wiel; P Houx; D L Knook; R G Westendorp Journal: J Neurol Neurosurg Psychiatry Date: 2001-07 Impact factor: 10.154
Authors: Kristine Yaffe; K Lindquist; A V Schwartz; C Vitartas; E Vittinghoff; S Satterfield; E M Simonsick; L Launer; C Rosano; J A Cauley; T Harris Journal: Neurology Date: 2011-09-07 Impact factor: 9.910
Authors: Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters Journal: Lancet Neurol Date: 2013-03-08 Impact factor: 44.182
Authors: Hannareeta Öhman; Niina Savikko; Timo E Strandberg; Hannu Kautiainen; Minna M Raivio; Marja-Liisa Laakkonen; Reijo Tilvis; Kaisu H Pitkälä Journal: J Am Geriatr Soc Date: 2016-04-01 Impact factor: 5.562